Mandate

Vinge acted for Carnegie and Kempen & Co in connection with BioInvent’s private placement of new shares

June 09, 2011

BioInvent International AB (publ) (NASDAQ OMX Stockholm) has completed a private placement of new shares with international institutional investors and qualified investors in Sweden through an accelerated bookbuilding procedure. Carnegie Investment Bank and Kempen & Co acted as Joint Global Co-ordinators and Joint Bookrunners.

Vinge and Latham & Watkins were legal advisors to the bookrunners. The Vinge team was headed by capital markets partner Erik Sjöman.

Related

Vinge advises Röko AB (publ) in connection with the establishment of its MTN programme

Vinge has advised Röko AB (publ) ("Röko") on the establishment of a medium-term note programme (the "MTN Programme") with a framework amount of SEK 5 billion.
November 13, 2026

Vinge advises Telavox on the sale of its Nordic customer base to Telia

Vinge has advised Telavox AB (“Telavox”) on the sale of Telavox’s Nordic customer base for business services to Telia Company AB (“Telia”). The customer base comprises approximately 24,000 business customers and 325,000 end users in Sweden, Denmark, Finland, and Norway. The purchase price amounts to SEK 3.8 billion plus a potential additional earn-out.
November 13, 2026

Vinge has advised Course Corrected VC on the establishment of Course Corrected VC Fund II

Vinge has advised Course Corrected VC on the establishment and structuring of their second fund, Course Corrected VC Fund II (the “Fund”).
November 12, 2026